NCT06049810

IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Randomized Withdrawal and Retreatment Phase III Clinical Trial Evaluating the Efficacy and Safety of Subcutaneous Injection of IBI112 in the Treatment of Moderate to Severe Plaque Psoriasis.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 566 (actual)
• Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of IBI112 in the treatment of participants with moderate to severe psoriasis

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	IBI112	Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& Dose 1 IBI112 through week 44
DRUG	IBI112/placebo	Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 on week 20 \& placebo through week 44 by subcutaneous injection
DRUG	IBI112/placebo	Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& placebo through week 44
DRUG	IBI112	Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 on week 20 \& Dose 1 IBI112 through week 44
DRUG	IBI112	Participants receive Dose 1 IBI112 through week 8 \& Dose 3 IBI112 through week 44
DRUG	IBI112	Participants receive Dose 1 IBI112 through week 8 \& Dose 2 IBI112 through week 44 by subcutaneous injection

Timeline

• Start date: 2023-10-10
• Primary completion: 2025-04-29
• Completion: 2025-07-28
• First posted: 2023-09-22
• Last updated: 2025-08-17

Locations

1 site across 1 country: China